2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170369
    SHO1122147 98%
    SHO1122147 (Compound 7m) affects the mitochondrial electron transport chain, exhibits mitochondrial uncoupling activity (EC50=3.6 μM), and increases the oxygen consumption rate (OCR=69%) and promotes cellular respiration. SHO1122147 is orally active, and can be used in reaearch of obesity and metabolic dysfunction-associated steatohepatitis (MASH).
    SHO1122147
  • HY-17037R
    Pirenzepine dihydrochloride (Standard) 29868-97-1 98%
    Pirenzepine (dihydrochloride) (Standard) is the analytical standard of Pirenzepine (dihydrochloride). This product is intended for research and analytical applications. Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells.
    Pirenzepine dihydrochloride (Standard)
  • HY-170448
    PROTAC AR Degrader-9 98%
    PROTAC AR Degrader-9 (Compound c6) is a PROTAC degrader for androgen receptor, that degrades AR in human hair follicle papilla cells (HDPCs) with a DC50 of 262.38 nM. PROTAC AR Degrader-9 promotes the expressions of paracrine factors, such as TGF-β1 and β-catenin, exhibits hair regenerating efficacy in mouse models.
    PROTAC AR Degrader-9
  • HY-170511
    GLP-1 receptor agonist 15 2757506-39-9 98%
    GLP-1 receptor agonist 15 (Example 4) is a GLP receptor agonist with an EC50 of 0.74 nM. The IC50 for the hERG potassium ion channel is 10.1 μM. GLP-1 receptor agonist 15 can be used for research in the field of diabetes.
    GLP-1 receptor agonist 15
  • HY-170516
    GLP-1 receptor agonist 16 2902596-52-3 98%
    GLP-1 receptor agonist 16 (Example 53) is a GLP-1 agonist. GLP-1 receptor agonist 16 can be used for the research of diabetes, obesity, or nonalcoholic steatohepatitis-related diseases[1].
    GLP-1 receptor agonist 16
  • HY-170571
    BE2647 98%
    BE2647 is a selective inhibitor for mitochondrial pyruvate carrier (MPC) with an EC50 of 70 nM. BE2647 exhibits good metabolic stability in mouse liver microsomes. BE2647 can be used in research of metabolic diseases, non-alcoholic fatty liver disease (MASLD), or non-alcoholic steatohepatitis (MASH).
    BE2647
  • HY-170572
    PB01 368434-78-0 98%
    PB01 is a DPP-4 inhibitor with an IC50 of 15.66 nM. It effectively inhibits high glucose-induced ROS production and mitochondrial superoxide formation while significantly reducing cellular DPP-4 expression. PB01 can also significantly lower blood glucose levels in diabetic mice. Additionally, PB01 demonstrates good safety, exhibiting almost no cytotoxicity at a concentration of 100 μM. PB01 holds potential for research in the field of diabetes.
    PB01
  • HY-170581
    PPARγ/δ modulator 2 98%
    PPARγ/δ modulator 2 (Compound 3h) is a PPARγ agonist and PPARδ antagonist. The Ki values for PPARγ and PPARδ are 2.8 μM and 43 nM, respectively. PPARγ/δ modulator 2 significantly enhances the production of Adiponectin and promotes adipogenic differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs). PPARγ/δ modulator 2 can be used in the study of metabolic disorders associated with hypoadiponectinemia.
    PPARγ/δ modulator 2
  • HY-170582
    PTP1B-IN-29 98%
    PTP1B-IN-29 (Compound A2B5) is an inhibitor for phosphatase, that inhibits protein tyrosine phosphatase 1B (PTP1B), TCPTP and λPPase with IC50s of 1.27 μM, 4.38 μM and 8.79 μM, respectively. PTP1B-IN-29 can be used in research of diabete and obesity.
    PTP1B-IN-29
  • HY-170588
    α-Glucosidase-IN-78 98%
    α-Glucosidase-IN-78 (Compound 12m) is an inhibitor for α-glucosidase with a reversible, competitive IC50 6.0 μM. α-Glucosidase-IN-78 can be used in research of diabete for its hypoglycemic property.
    α-Glucosidase-IN-78
  • HY-170593
    ChREBPα/14-3-3 regulator-1 3067202-14-3 98%
    ChREBPα/14-3-3 regulator-1 (Compound 43) is a selective molecular gel that can stabilize the interaction of carbohydrate response element binding protein (ChREBP) with 14-3-3 proteins (EC50: 3.8 μM). ChREBPα/14-3-3 regulator-1 effectively protects β cells from glucolipotoxicity and maintains cell function, and can be used in the study of type 2 diabetes.
    ChREBPα/14-3-3 regulator-1
  • HY-170606
    α-Glucosidase-IN-79 98%
    α-Glucosidase-IN-79 (Compound 4d9) is a non-competitive α-Glucosidase inhibitor with an IC50 of 2.11 μM, which is more potent than existing α-Glucosidase inhibitors such as Acarbose (HY-B0089) (IC50 of 327.0 μM) and HXH8r (IC50 of 15.32 μM). α-Glucosidase-IN-79 is non-cytotoxic to human normal hepatocyte (LO2) cells and shows good metabolic stability in rat plasma. α-Glucosidase-IN-79 holds promise for research into type 2 diabetes.
    α-Glucosidase-IN-79
  • HY-170622
    1,2-Distearoyl-3-decanoyl-rac-glycerol 127931-28-6 98%
    1,2-Distearoyl-3-decanoyl-rac-glycerol is a triacylglycerol containing Stearic acid (HY-B2219) and Decanoic acid (HY-W015309).
    1,2-Distearoyl-3-decanoyl-rac-glycerol
  • HY-170626
    1-Palmitoyl-3-butyryl-rac-glycerol 20358-82-1 98%
    1-Palmitoyl-3-butyryl-rac-glycerol is a diacylglycerol that contains Palmitic acid (HY-N0830) and Butyric acid (HY-B0350).
    1-Palmitoyl-3-butyryl-rac-glycerol
  • HY-170630
    1,3-Di-9(E)-palmitoleoyl glycerol 372490-69-2 98%
    1,3-Di-9(E)-palmitoleoyl glycerol is a diacylglycerol that contains Palmitelaidic acid (HY-N2341).
    1,3-Di-9(E)-palmitoleoyl glycerol
  • HY-170642
    Trimyristolein 99483-10-0 98%
    Trimyristolein (1,2,3-Trimyristoleoyl glycerol) is a triacylglycerol that contains Myristoleic acid (HY-113332).
    Trimyristolein
  • HY-170692
    Hypoglycemic agent 3 98%
    Hypoglycemic agent 3 (Compound H26), a derivative of corosolic acid, exhibits lipid-lowering and significant hypoglycemic effects and can be used as a hypoglycemic agent. Hypoglycemic agent 3 inhibits insulin resistance by targeting MCCC1 and can be used in the study of type 2 diabetes.
    Hypoglycemic agent 3
  • HY-170797
    α-Glucosidase-IN-80 98%
    α-Glucosidase-IN-80 (Compound 10n) is a potent competitive inhibitor of α-glucosidase, with an IC50 of 48.4 μM. α-Glucosidase-IN-80 has good pharmacokinetic properties and toxicity profiles and can be used in the research of diabetes-related diseases.
    α-Glucosidase-IN-80
  • HY-170866
    α-Glucosidase-IN-81 98%
    α-Glucosidase-IN-81 (Compound 5) is a potent α-Glucosidase inhibitor with an IC50 value of 5.30 μM. α-Glucosidase-IN-81 is promising for research of diabetes.
    α-Glucosidase-IN-81
  • HY-170874
    PPARγ modulator-2 2897652-01-4 98%
    PPARγ modulator-2 (Compound (R)-2n) is the reversible modulator for PPARγ that inhibits PPARγ ligand-binding domain (LBD) with an IC50 of 41 nM. PPARγ modulator-2 reduces blood glucose, improves the glucose tolerance and insulin tolerance, and exhibits anti-diabetic efficacy in db/db mouse models.
    PPARγ modulator-2
Cat. No. Product Name / Synonyms Application Reactivity